Article Contents ::
- 1 Details About Generic Salt :: Amobarbi
- 2 Main Medicine Class:: Sedative and hypnotic,barbiturate
- 3 (am-oh-BAR-bih-tahl SO-dee-uhm) Amytal Sodium Class: Sedative and hypnotic/barbiturate
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Amobarbi
Main Medicine Class:: Sedative and hypnotic,barbiturate
(am-oh-BAR-bih-tahl SO-dee-uhm)
Amytal Sodium
Class: Sedative and hypnotic/barbiturate
Drugs Class ::
Action Depresses sensory cortex; decreases motor activity; alters cerebellar function and produces drowsiness, sedation and hypnosis.
Indications for Drugs ::
Indications Relief of anxiety; short-term therapy for insomnia; induction of preanesthetic sedation.
Drug Dose ::
Route/Dosage
INSOMNIA
ADULTS: PO/IM/IV 65 to 200 mg at bedtime.
SEDATION
ADULTS: PO/IM/IV 30 to 50 mg bid or tid. CHILDREN: PO/IM 2 to 6 mg/kg/dose.
Contraindication ::
Contraindications Hypersensitivity to barbiturates; history of addiction to sedative-hypnotic drugs; history of porphyria; severe liver impairment; respiratory disease with dyspnea; patients with nephritis.
Drug Precautions ::
Precautions
Pregnancy: Category D. Lactation: Excreted in breast milk. Children: Safety and efficacy not established in children < 6 yr. Elderly: Reduce dosage. Drug dependence: Tolerance or psychologic and physical dependence may occur with continued use. Renal or hepatic impairment: Use with caution; reduce dosage.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CV: Bradycardia; hypotension; syncope. CNS: Drowsiness; agitation; confusion; headache; hyperkinesia; ataxia; CNS depression; paradoxical excitement; nightmares; psychiatric disturbances; hallucinations; insomnia; dizziness. GI: Nausea; vomiting; constipation. HEMA: Blood dyscrasias (agranulocytosis, thrombocytopenia). HEPA: Liver damage. RESP: Hypoventilation; apnea; laryngospasm; bronchospasm. OTHER: Hypersensitivity reactions (eg, angioedema, rashes, exfoliative dermatitis); fever; injection site reactions (eg, local pain, thrombophlebitis).
Drug Mode of Action ::
Action Depresses sensory cortex; decreases motor activity; alters cerebellar function and produces drowsiness, sedation and hypnosis.
Drug Interactions ::
Interactions
Alcohol, CNS depressants: Depressant effects of these drugs may be enhanced. Anticoagulants, beta-blockers, calcium-channel blockers (eg, Verapamil) theophyllines: Activity of these drugs may be reduced. Anticonvulsants: Serum concentrations of carbamazepine, valproic acid and succinimides may be reduced. Valproic acid may increase barbiturate serum levels. Corticosteroids: Effectiveness may be reduced. Estrogens, estrogen-containing oral contraceptives: Effectiveness may be reduced.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Ensure that serum bilirubin level has been determined before beginning long-term therapy, especially in patients with hepatic disease.
- Monitor vital signs before and during IV infusion.
- Assess sleep patterns and mental status before beginning therapy and monitor periodically during therapy.
- Observe IV site during and after infusion. Extravasation or inadvertent intra-arterial injection may cause tissue necrosis, arterial spasm, thrombosis, or gangrene.
- Monitor children and elderly patients for adverse reactions, including marked excitement, confusion, restlessness, or depression.
- If hypersensitivity reaction develops, withhold dose and notify physician.
- When administering by IV infusion, keep resuscitation equipment at bedside.
- If signs of extravasation or phlebitis appear at injection site, discontinue IV infusion and notify physician.
- Implement safety measures to prevent falls, especially with elderly patients.
- Restrict amount of drug available to patient during early therapy.
|
Drug Storage/Management ::
Administration/Storage
- May be given in oral, IM (deep), or IV form. Do not administer SC.
- Reconstitute solution with Sterile Water for Injection, rotating vial to mix. Do not shake vial. Solution should clear within 5 min.
- Do not dilute with Lactated Ringer’s solution.
- Do not administer if solution is discolored or if precipitate is present.
- After reconstitution, inject solution within 30 min.
- Do not exceed IV infusion rate of 1 ml/min or 100 mg/min. Over-rapid administration may result in respiratory depression, apnea, and hypertension.
- To avoid tissue irritation, do no inject > 5 ml IM into any one site.
- Store at room temperature. Do not freeze.
Drug Notes ::
Patient/Family Education
- Advise patient not to increase dosage or stop therapy without advice of physician.
- Instruct patient to avoid alcohol, nicotine, and caffeine products.
- Advise patient that drug may cause drowsiness, and to use caution while driving or performing other tasks requiring mental alertness.
- Inform patient to report the following symptoms to physician: Excessive sleepiness, fatigue, nausea, vomiting.